Drawing for Serial No. 79439124

USPTO serial 79439124

Serial No. 79439124

Reviewed by CopyMark Law Group

Status 645Office Action
Filing date
Status date
Registration date
—
Examiner
BLAZICH, JOAN MICHELE
Law office
TMO LAW OFFICE 122

What this means

The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.

Status 645: Status 645 means the USPTO mailed a final refusal maintaining at least one objection to your application. You can respond, appeal to the Trademark Trial and Appeal Board, or allow the application to abandon.

Need help with Serial No. 79439124?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Miriam D. Trudell

Miriam D. Trudell Davis Graham & Stubbs LLP3400 Walnut Street, Suite 700Denver, CO 80205United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals for antibiotics, antifungal preparations, anti-viral agents, pharmaceutical preparations for treating diabetes, pharmaceutical preparations for treating hypertension, antihypertensives preparations, lipid lowering agents, antithrombotic preparation gastro-intestinal treatment preparations, analgesics, anti-inflammatory preparations, antiallergic medicines, pharmaceutical preparations for treating allergic rhinitis, asthma treatment preparations, pharmaceutical preparations for the treatment of rhinitis, preparations for the treatment of osteoporosis, pharmaceutical preparations acting on the central nervous system, pharmaceutical preparations for treating peripheral nervous system disorders, pharmaceutical preparations for the prevention of disorders of the nervous system, cardiovascular pharmaceutical preparations, anti-cancer preparations, local anesthetics preparations, sedatives preparations, dermatological pharmaceutical preparation, muscle relaxants preparations, hepatitis vaccine; pharmaceutical preparations for the treatment of the digestive system; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations for the treatment of the circulatory system; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the treatment of disorders of the genitourinary system; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the prevention of diabetes; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of Parkinson's disease; preparations for treatment of hepatitis; pharmaceutical for the treatment of erectile dysfunction; dietary supplement drinks; nutritional supplements; therapeutic drugs and agents in the nature of therapeutic pharmaceutical and agents for treating infectious diseases, skeletal and muscular disorders, cardiovascular and circulatory diseases, nervous system diseases, ocular disorders, respiratory diseases, gastrointestinal diseases, endocrine diseases, kidney diseases, hormonal diseases, and oncological diseases and disorders, pharmaceutical preparations for the treatment of musculoskeletal disorders, preparations for the treatment of hypercholesteremia; pharmaceutical agents affecting metabolism; vitamin and mineral supplements; medicinal healthcare preparations for supporting nutritional balance and overall well-being, namely, vitamin preparations, multivitamin preparations, nutritional supplements, dietary and nutritional supplements, protein dietary supplements, nutritional supplement energy bars, and powdered nutritional supplement drink mixes; nutraceutical preparations for use as a dietary supplement for therapeutic or medical purposes; nutraceuticals for use as a dietary supplementACTIVE—
035Wholesale store services featuring pharmaceuticals; retail store services featuring pharmaceuticals; wholesale store services featuring pharmaceutical preparations for health care; retail store services featuring pharmaceutical preparations for health care; wholesale store services featuring dietary supplement drinks; retail store services featuring dietary supplement drinks; wholesale store services featuring nutritional supplements; retail store services featuring nutritional supplements; wholesale store services featuring nutraceuticals for use as a dietary supplement; retail store services featuring nutraceuticals for use as a dietary supplement; administrative processing of purchase orders; promoting the goods and services for others by means of operating an on-line comprehensive shopping mall with links to the retail web sites for others; business intermediary services relating to mail order by telecommunications, namely, services featuring pharmaceutical productsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 11, 2026GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Sep 11, 2026GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 11, 2026CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 14, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 14, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 14, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 5, 2026RFNTREFUSAL PROCESSED BY IB—
Feb 14, 2026RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Feb 14, 2026RFRRREFUSAL PROCESSED BY MPU—
Jan 21, 2026RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 20, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 16, 2026DOCKASSIGNED TO EXAMINER—
Dec 15, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 15, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 11, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance